FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Grant Skrepnek

Research Profile

Geographic Areas

United States

Concepts & Ideas

Physiology

Drug Interactions

Activities & Behaviors

Cost Benefit Analysis

Chemicals & Drugs

Procedures

Hospitalization

Organizations

Objects

Hospitals, Veterans

Co-author Network

Publications

TOP 3
Gary M Owens; Eleanor L Olvey; Grant H Skrepnek; Michael W Pill
Perspectives for managed care organizations on the burden of multiple sclerosis and the cost-benefits of disease-modifying therapies.
Christopher J Barnes; Christina Caon; John F Foley; Mark Friedman; Joseph Menzin; Kavita V Nair; Christine Nichols; Eleanor L Olvey; Gary M Owens; Michael W Pill; Grant H Skrepnek; Leigh Ann White; Kristine Zerkowski
Intramuscular interferon beta-1a and evolving treatment options and outcomes measurement for MS: considerations for managed care.
Edward P Armstrong; Medha Sasane; Grant H Skrepnek; Susan M Snodgrass; Samir K Ballas
Long-term persistency and costs associated with the use of iron chelation therapies in the treatment of Sickle cell disease within Medicaid programs.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Grant Skrepnek (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Gary M Owens; Eleanor L Olvey; Grant H Skrepnek; Michael W Pill
Perspectives for managed care organizations on the burden of multiple sclerosis and the cost-benefits of disease-modifying therapies.
Journal of managed care pharmacy : JMCP 2013;19(1 Suppl A):S41-53.
2013: Christopher J Barnes; Christina Caon; John F Foley; Mark Friedman; Joseph Menzin; Kavita V Nair; Christine Nichols; Eleanor L Olvey; Gary M Owens; Michael W Pill; Grant H Skrepnek; Leigh Ann White; Kristine Zerkowski
Intramuscular interferon beta-1a and evolving treatment options and outcomes measurement for MS: considerations for managed care.
Journal of managed care pharmacy : JMCP 2013;19(1 Suppl A):S1-53.
2013: Edward P Armstrong; Medha Sasane; Grant H Skrepnek; Susan M Snodgrass; Samir K Ballas
Long-term persistency and costs associated with the use of iron chelation therapies in the treatment of Sickle cell disease within Medicaid programs.
Journal of medical economics 2013;16(1):10-8.
2012: Derek H Tang; Sean Sullivan; David S Alberts; Rick Nevins; Grant H Skrepnek
Health care expenditures, hospitalizations, and productivity associated with cancer in US employer settings.
Journal of occupational and environmental medicine / American College of Occupational and Environmental Medicine 2012;54(12):1453-60.
2012: Albert Amini; Rainer W Gruessner; Tun Jie; Felipe B Maegawa; Asad E Patanwala; Grant H Skrepnek; Evan S Ong
Effect of epidural analgesia on postoperative complications following pancreaticoduodenectomy.
American journal of surgery 2012;204(6):1000-4; discussion 1004-6.
2012: Karalea D Jasiak; Anna C Christich; Christopher J Edwards; Hanna Phan; Grant H Skrepnek; Asad E Patanwala
Induction dose of propofol for pediatric patients undergoing procedural sedation in the emergency department.
Pediatric emergency care 2012;28(5):440-2.
2012: Prasadini N Perera; Duane L Sherrill; Edward P Armstrong; Grant H Skrepnek
Acute exacerbations of COPD in the United States: inpatient burden and predictors of costs and mortality.
COPD 2012;9(2):131-41.
2010: Grant H Skrepnek; Brian Seal; Muralikrishna Tangirala; Marjorie K Jeffcoat; Nelson B Watts; Joel W Hay
Adverse events and intravenous versus oral bisphosphonate use in patients with osteoporosis and cancer in the U.S.
General dentistry 2010;58(6):484-92; quiz 493-4.
2010: Lisa M Hess; Daniel C Malone; Grant H Skrepnek; Pamela G Reed; Edward Armstrong; Stephen Joel Coons
Oncologist preferences for health states associated with the treatment of advanced ovarian cancer.
Applied health economics and health policy 2010;8(4):217-23.
2008: Yu Ko; Daniel C Malone; Jerome V D'Agostino; Grant H Skrepnek; Edward P Armstrong; Mary Brown; Raymond L Woosley
Potential determinants of prescribers' drug-drug interaction knowledge.
Research in social & administrative pharmacy : RSAP 2008;4(4):355-66.
2008: Eleanor L Olvey; Grant H Skrepnek
The cost-effectiveness of sertraline in the treatment of depression.
Expert opinion on pharmacotherapy 2008;9(14):2497-508.
2008: Maysaa H Mahmood; Edward P Armstrong; Daniel C Malone; Grant H Skrepnek
Relationship between pharmaceutical services characteristics and exposure rates to drug-drug interactions in Veterans Affairs medical centers.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 2008;65(18):1744-9.
2008: Eleanor L Olvey; Grant H Skrepnek; Paul E Nolan
Cost-effectiveness of urokinase and alteplase for treatment of acute peripheral artery disease: comparison in a decision analysis model.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 2008;65(15):1435-42.
2008: MT Wang; Grant H Skrepnek; Edward Armstrong; Duane L Sherrill; Robin B Harris; Cheng-Liang Tsai; Daniel C Malone
Use of salmeterol with and without concurrent use of inhaled corticosteroids and the risk of asthma-related hospitalization among patients with asthma.
Current medical research and opinion 2008;24(3):859-67.
2008: Yu Ko; Daniel C Malone; Grant H Skrepnek; Edward P Armstrong; John E Murphy; Jacob Abarca; Rick A Rehfeld; Sally J Reel; Raymond L Woosley
Prescribers' knowledge of and sources of information for potential drug-drug interactions: a postal survey of US prescribers.
Drug safety : an international journal of medical toxicology and drug experience 2008;31(6):525-36.
2007: Amy J Grizzle; Maysaa H Mahmood; Yu Ko; John E Murphy; Edward P Armstrong; Grant H Skrepnek; William N Jones; Gregory P Schepers; W Paul Nichol; Antoun Houranieh; Donna C Dare; Christopher T Hoey; Daniel C Malone
Reasons provided by prescribers when overriding drug-drug interaction alerts.
The American journal of managed care 2007;13(10):573-8.
2007: Maysaa Mahmood; Daniel C Malone; Grant H Skrepnek; Jacob Abarca; Edward P Armstrong; John E Murphy; Amy J Grizzle; Yu Ko; Raymond L Woosley
Potential drug-drug interactions within Veterans Affairs medical centers.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 2007;64(14):1500-5.
2007: Wei-Shi Yeh; Edward P Armstrong; Grant H Skrepnek; Daniel C Malone
Peginterferon alfa-2a versus peginterferon alfa-2b as initial treatment of hepatitis C virus infection: a cost-utility analysis from the perspective of the Veterans Affairs Health Care System.
Pharmacotherapy 2007;27(6):813-24.
2007: Lisa M Hess; M Benham-Hutchins; T J Herzog; C-H Hsu; Daniel C Malone; Grant H Skrepnek; Marion K Slack; David S Alberts
A meta-analysis of the efficacy of intraperitoneal cisplatin for the front-line treatment of ovarian cancer.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2007;17(3):561-70.
2007: Daniel C Malone; Jacob Abarca; Grant H Skrepnek; John E Murphy; Edward P Armstrong; Amy J Grizzle; Rick A Rehfeld; Raymond L Woosley
Pharmacist workload and pharmacy characteristics associated with the dispensing of potentially clinically important drug-drug interactions.
Medical care 2007;45(5):456-62.
2007: Cecilia M Plaza; Jolaine Reierson Draugalis; Marion K Slack; Grant H Skrepnek; Karen Ann Sauer
Use of reflective portfolios in health sciences education.
American journal of pharmaceutical education 2007;71(2):34.
2007: Cecilia M Plaza; Jolaine Reierson Draugalis; Marion K Slack; Grant H Skrepnek; Karen Ann Sauer
Curriculum mapping in program assessment and evaluation.
American journal of pharmaceutical education 2007;71(2):20.
2007: Edward P Armstrong; Grant H Skrepnek; M Haim Erder
Cost-utility comparison of escitalopram and sertraline in the treatment of major depressive disorder.
Current medical research and opinion 2007;23(2):251-8.
2007: Daniel Ventura; Edward P Armstrong; Grant H Skrepnek; M Haim Erder
Escitalopram versus sertraline in the treatment of major depressive disorder: a randomized clinical trial.
Current medical research and opinion 2007;23(2):245-50.
2007: Grant H Skrepnek
The contrast and convergence of Bayesian and frequentist statistical approaches in pharmacoeconomic analysis.
PharmacoEconomics 2007;25(8):649-64.
2007: William J Elliott; Craig A Plauschinat; Grant H Skrepnek; Douglas Gause
Persistence, adherence, and risk of discontinuation associated with commonly prescribed antihypertensive drug monotherapies.
Journal of the American Board of Family Medicine : JABFM 2007;20(1):72-80.
2006: Grant H Skrepnek; Edward P Armstrong; Daniel C Malone; Jacob Abarca; John E Murphy; Amy J Grizzle; Rick A Rehfeld; Raymond L Woosley
Workload and availability of technology in metropolitan community pharmacies.
Journal of the American Pharmacists Association : JAPhA 2006;46(2):154-60.
2006: Jacob Abarca; Daniel C Malone; Grant H Skrepnek; Rick A Rehfeld; John E Murphy; Amy J Grizzle; Edward P Armstrong; Raymond L Woosley
Community pharmacy managers' perception of computerized drug-drug interaction alerts.
Journal of the American Pharmacists Association : JAPhA 2006;46(2):148-53.
2005: Grant H Skrepnek; Jacob Abarca; Daniel C Malone; Edward P Armstrong; Farshad M Shirazi; Raymond L Woosley
Incremental effects of concurrent pharmacotherapeutic regimens for heart failure on hospitalizations and costs.
The Annals of pharmacotherapy 2005;39(11):1785-91.
2005: Grant H Skrepnek
Cost-effectiveness of HMG-CoA reductase inhibitors in the treatment of dyslipidemia and prevention of CHD.
Expert review of pharmacoeconomics & outcomes research 2005;5(5):603-23.
2005: Grant H Skrepnek
Regression methods in the empiric analysis of health care data.
Journal of managed care pharmacy : JMCP 2005;11(3):240-51.
2005: Grant H Skrepnek; Erin E Ballard
Cost-efficacy of imatinib versus allogeneic bone marrow transplantation with a matched unrelated donor in the treatment of chronic myelogenous leukemia: a decision-analytic approach.
Pharmacotherapy 2005;25(3):325-34.
2005: Grant H Skrepnek; Edward P Armstrong; Daniel C Malone; Sulabha Ramachandran
An economic and outcomes assessment of first-line monotherapy in the treatment of community-acquired pneumonia within managed care.
Current medical research and opinion 2005;21(2):261-70.
2004: Grant H Skrepnek; Stan V Skrepnek
An assessment of therapeutic regimens in the treatment of acute exacerbations in chronic obstructive pulmonary disease and asthma.
The American journal of managed care 2004;10(5 Suppl):S139-52.
2004: Grant H Skrepnek; Stan V Skrepnek
Epidemiology, clinical and economic burden, and natural history of chronic obstructive pulmonary disease and asthma.
The American journal of managed care 2004;10(5 Suppl):S129-38.
2004: Grant H Skrepnek
Accounting- versus economic-based rates of return: implications for profitability measures in the pharmaceutical industry.
Clinical therapeutics 2004;26(1):155-74.
2003: Lydia K Lai; Edward P Armstrong; Amista Lone Salcido; Rachel French; Grant H Skrepnek
Women's perception of bone-mineral density testing and osteoporosis education in the community pharmacy.
The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists 2003;18(11):968-76.